ADC-2419 / CSPC Pharma - LARVOL DELTA

A first-in-class IKZF1/3 degrader antibody conjugate (DAC) as a potential myeloma treatment (AACR 2026) - "From a panel of candidate payloads, we identified P5 that binds CRBN with an 80-fold higher affinity (Kd <10 nM) than lenalidomide. Furthermore, pronounced tumor accumulation was observed in tumor-bearing mice, aligning with the in vivo efficacy and validating the targeted-delivery capability of our DAC platform. Collectively, the robust preclinical evidence for ADC-2419, which synergizes antibody targeting with catalytic protein degradation, supports its translational promise in overcoming key limitations in myeloma treatment."

Hematological Malignancies • Multiple Myeloma • Oncology • CRBN • CTSC • IKZF1 • IKZF3